Request Trial

Marisa Woutersen

Key details

Marisa Woutersen is a senior reporter for Life Sciences Intellectual Property Review and World IP Review. She largely covers intellectual property developments across the global life sciences sector, including pharmaceuticals, biotechnology, medtech, AI, M&A and regulation.

Since joining Newton Media in 2023, Marisa has reported across a wide range of topics, from the rise of generative AI and its impact on the creative industries to the crossover between intellectual property and sport, including issues affecting athletes, as well as global pharmaceutical disputes, vaccine technology, access to medicines and life sciences M&A.

She has reported live from court and regularly travels to international conferences, where she interviews lawyers, business leaders and other key industry figures.

Marisa holds a Master’s in International Law and a BA in Politics and International Relations from the University of Sussex, and is currently completing her NCTJ Diploma in Journalism.

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Total results: 456

Articles by Marisa Woutersen

Dr Reddy’s eyes appeal stakes as Boehringer hearing ends
Pharma
Dr Reddy’s eyes appeal stakes as Boehringer hearing ends
Questions over what Boehringer’s patents actually proved dominated the final day of the hearing, but a push for a further finding raised the stakes, with a possible appeal threatening to keep Dr Reddy’s off the market even if it won.   22 October 2026
Amarin and Hikma call time on six-year skinny label fight
Pharma
Amarin and Hikma call time on six-year skinny label fight
Following a major US Supreme Court win for generics, the landmark dispute has finally come to an end. A new filing brings closure to a case that raised questions over skinny labelling and induced patent infringement.   22 October 2026
WATCH: Medmix global IP head on building business-focused IP teams
In-house counsel
WATCH: Medmix global IP head on building business-focused IP teams
From building IP teams that are business orientated to tackling M&A challenges, the global head of IP management at Medmix Group—a manufacturer of high-precision delivery, mixing and application devices—explains why close collaboration, trusted external counsel and thorough due diligence matter.   21 October 2026
MedTech
Fed Circ refuses to rehear Insulet’s $59.4m trade secret loss
A panel rejected the Omnipod maker’s request for a rehearing in its trade secrets dispute with South Korean insulin pump maker EOFlow, leaving in place a ruling that overturned a $59.4 million damages award and raising questions over the three-year statute of limitations under the DTSA.   20 October 2026
Pharma
Boehringer accuses Dr Reddy’s of ‘weaponising’ plausibility
In closing arguments last week, the drugmaker urged the UK Patents Court to reject an overly critical approach to plausibility and consider what its patents disclose when read as a whole rather than individually.   20 October 2026
MedTech
Align Technology notches another win in escalating clear aligner feud
The US clear aligner giant has dealt another blow to a Chinese rival, securing an infringement ruling at the UPC as the pair wage a growing patent dispute across Europe, the US and China.   19 October 2026
Biotech
Guardant loses second patent challenge to TwinStrand amid $245m damages fallout
All 30 claims of a key DNA sequencing patent have been upheld for a second time, marking another setback in a long-running dispute that has already left Guardant facing a $245 million bill.   16 October 2026
Pharma
Boehringer and Dr Reddy’s spar over plausibility as trial wraps up
A dispute over missing experimental data and patent disclosures draws to a close as Boehringer and Dr Reddy’s deliver their final arguments. The court’s decision could bring greater clarity to the UK approach to plausibility and determine whether Dr Reddy’s can move ahead with its proposed generic launch.   15 October 2026
Careers
Haynes Boone expands in California with new office
Growing demand from life sciences and healthcare clients prompts an expansion in California, bringing the firm closer to biotechnology companies, research institutions and key courts for its Southern California litigators.   14 October 2026
Pharma
Accord’s generic hopes dashed in cyanide antidote ruling
Efforts to bring a generic cyanide poisoning treatment to market have suffered a setback after a US judge rejected challenges to three patents and criticised the drugmaker’s interpretation of the treatment’s chemical composition.   14 October 2026

Not finding what you're looking for, please try resetting your applied search and filters,
or try the full site search.